Wiley Bros. Aintree Capital, LLC Virios Therapeutics, Inc. Transaction History
Wiley Bros. Aintree Capital, LLC
- $718 Million
- Q1 2024
A detailed history of Wiley Bros. Aintree Capital, LLC transactions in Virios Therapeutics, Inc. stock. As of the latest transaction made, Wiley Bros. Aintree Capital, LLC holds 11,000 shares of VIRI stock, worth $2,530. This represents 0.0% of its overall portfolio holdings.
Number of Shares
11,000
Previous 11,000
-0.0%
Holding current value
$2,530
Previous $6,000
16.67%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding VIRI
# of Institutions
22Shares Held
681KCall Options Held
0Put Options Held
0-
Vanguard Group Inc Valley Forge, PA209KShares$48,0430.0% of portfolio
-
Geode Capital Management, LLC Boston, MA174KShares$40,1270.0% of portfolio
-
State Street Corp Boston, MA52.8KShares$12,1500.0% of portfolio
-
Mc Collum Christoferson Group LLC Amherst, NY42KShares$9,6600.01% of portfolio
-
Raymond James & Associates St Petersburg, FL30KShares$6,9000.0% of portfolio
About Virios Therapeutics, Inc.
- Ticker VIRI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 18,330,400
- Market Cap $4.22M
- Description
- Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It is also developing IMC...